Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model-Reference-Cited by-同舟云学术

Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model

Published:2018-01-25 Issue:1 Volume:13 Page:e0187063
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Kim Jinil,Choi Sang Hyun,Ham Su Jung,Cho Young Chul,Lee Seul-I,Kang Jeeheon,Woo Dong-Cheol,Lee Weon Sub,Yoo Jin-San,Kim Kyung Won^ORCID,Choi Yoonseok

Funder

Ministry of Health and Welfare

Ministry of Education

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference36 articles.

1. Tumour vascularity and proliferation: clear evidence of a close relationship;N Weidner;J Pathol,1999

2. Clinical advances in the development of novel VEGFR2 inhibitors;C Fontanella;Annals of translational medicine,2014

3. Basic and therapeutic aspects of angiogenesis;M Potente;Cell,2011

4. Hallmarks of cancer: the next generation;D Hanahan;Cell,2011

5. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics;Z Zhu;Curr Cancer Drug Targets,2002

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Anti-Angiogenic Activity of Drugs in Multiple Myeloma;Cancers;2023-03-27

3. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials;Frontiers in Oncology;2019-06-21